Literature DB >> 7870045

Different subunit requirements for volatile and nonvolatile anesthetics at gamma-aminobutyric acid type A receptors.

B D Harris1, G Wong, E J Moody, P Skolnick.   

Abstract

The ability of volatile (halothane and isoflurane) and nonvolatile (alphaxalone and pentobarbital) general anesthetics to modulate radioligand binding to gamma-aminobutyric acid (GABA)A receptors was examined in an immortalized cell line (WSS-1) expressing rat alpha 1 and gamma 2 subunits. Volatile anesthetics enhance [3H]flunitrazepam binding to WSS-1 cells in a concentration-dependent manner, with potencies and efficacies comparable to those found with native GABAA receptors. Transfection of these cells with cDNAs encoding rat beta 2 or beta 3 subunits had a significant influence on anesthetic efficacy but not potency in this assay. Thus, transfection with the beta 2 subunit reduced the efficacy of both isoflurane and halothane, whereas transfection with the beta 3 subunit increased the efficacy of isoflurane but not halothane, compared with values obtained in WSS-1 cells. In contrast, alpha-xalone (an anesthetic steroid) had no effect, whereas at high concentrations pentobarbital (an anesthetic barbiturate) produced a modest inhibition of [3H]flunitrazepam binding to GABAA receptors in WSS-1 cells. Transfection of WSS-1 cells with cDNAs encoding either beta 2 or beta 3 subunits resulted in a concentration-dependent enhancement of [3H]flunitrazepam binding by these nonvolatile anesthetics. Moreover, pentobarbital was significantly more potent in enhancing [3H]flunitrazepam binding to WSS-1 cells transfected with the beta 2 subunit, compared with the beta 3 subunit. The difference in subunit requirements between volatile and nonvolatile anesthetics for enhancement of [3H]flunitrazepam binding indicates that these classes of agents affect GABAA receptor function at distinct loci. These studies also provide evidence that the beta subunit is required for these nonvolatile anesthetics to positively modulate GABAA receptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7870045

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

Review 1.  General anaesthetic actions on ligand-gated ion channels.

Authors:  M D Krasowski; N L Harrison
Journal:  Cell Mol Life Sci       Date:  1999-08-15       Impact factor: 9.261

Review 2.  [The GABA(A) receptor family: possibilities for the development of better anesthetics].

Authors:  B Drexler; C Grasshoff; U Rudolph; K Unertl; B Antkowiak
Journal:  Anaesthesist       Date:  2006-03       Impact factor: 1.041

3.  Effects of anesthetics on the structure of a phospholipid bilayer: molecular dynamics investigation of halothane in the hydrated liquid crystal phase of dipalmitoylphosphatidylcholine.

Authors:  K Tu; M Tarek; M L Klein; D Scharf
Journal:  Biophys J       Date:  1998-11       Impact factor: 4.033

4.  Diazepam enhancement of GABA-gated currents in binary and ternary GABAA receptors: relationship to benzodiazepine binding site density.

Authors:  R Granja; D Gunnersen; G Wong; A Valeyev; P Skolnick
Journal:  J Mol Neurosci       Date:  1997-12       Impact factor: 3.444

Review 5.  Neurosteroid modulation of native and recombinant GABAA receptors.

Authors:  J J Lambert; D Belelli; C Hill-Venning; H Callachan; J A Peters
Journal:  Cell Mol Neurobiol       Date:  1996-04       Impact factor: 5.046

6.  Biphasic modulation of GABA(A) receptor binding by steroids suggests functional correlates.

Authors:  S Srinivasan; D W Sapp; A J Tobin; R W Olsen
Journal:  Neurochem Res       Date:  1999-11       Impact factor: 3.996

7.  Comparative modulation by 3 alpha,5 alpha and 3 beta,5 beta neurosteroids of GABA binding sites during avian central nervous system development.

Authors:  M S Viapiano; S Fiszer de Plazas
Journal:  Neurochem Res       Date:  1998-02       Impact factor: 3.996

8.  GABA(A) receptors in normal development and seizures: friends or foes?

Authors:  Aristea S Galanopoulou
Journal:  Curr Neuropharmacol       Date:  2008-03       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.